GLP-1 Therapies: Targeting Metabolic Disease 

GLP-1 receptor agonists are prescription medicines designed to mimic glucagon-like peptide-1, a hormone naturally released after eating. By activating GLP-1 receptors, these medicines help regulate blood glucose, slow gastric emptying, and increase feelings of fullness. These medicines are used in approved clinical contexts including type 2 diabetes and, for some products, weight management 

The emergence of medicines such as semaglutide, liraglutide, and dual agonists such as tirzepatide has become an important area of clinical research and care, with ongoing clinical research is evaluating potential benefits across cardiovascular disease, chronic kidney disease, obstructive sleep apnea, and other obesity-related conditions. 

FDA-Approved GLP-1 Medications: Precision at Every Step 

FDA-approved GLP-1 therapies are produced under strict Good Manufacturing Practice (GMP) conditions, with tightly controlled processes designed to ensure consistent quality across manufacturing batches. From peptide synthesis through to final packaging, each stage of manufacturing is validated against defined specifications for potency, sterility, and stability. 

These medicines are also supported by extensive clinical trial programs assessing safety, pharmacokinetics, pharmacodynamics, and long-term outcomes, including effects on glycemic control, weight, and cardiovascular risk. Taken together, this regulatory and clinical framework ensures that approved GLP-1 therapies are developed as fully validated pharmaceutical products with consistent performance in clinical use. 

Why Have GLP-1 Medications Been Compounded? 

As the popularity of GLP-1s for diabetes and weight management increased, periods of drug shortages limited the availability of some FDA-approved products. In the US, federal policy has allowed certain compounding activity during drug shortages and under specific legal conditions.  However, FDA has stated  that the semaglutide and tirzepatide injection product shortages have been resolved, and that compounders may face enforcement action where compounded products are essentially copies of approved medicines.  

For some Patients, compounding may be considered in limited patient-specific circumstances where legally permitted and clinically appropriate when commercially available products did not meet individual clinical needs, such as requiring a different dosage strength or avoiding certain inactive ingredients.  

While compounding can improve access in these situations, it is important to recognize that compounded GLP-1 medications are not FDA-approved and do not undergo the same premarket review or manufacturing validation as commercially manufactured products.  

What About Creatine? Isn’t That “Compounded” Too? 

Creatine offers an interesting bridge in this discussion because it highlights how the word compound can mean different things depending on context. 

Creatine is a naturally occurring chemical compound that plays a central role in energy production by replenishing the primary energy-carrying molecule during high-intensity activity. Unlike GLP-1s, it does not affect appetite or blood sugar regulation, but it supports muscle energy production. 

Creatine fits into the broader compounding conversation because it is often used in customized nutritional formulations with electrolytes, amino acids, or carbohydrates to support specific training or recovery needs. While not a “compounded drug,” it reflects the same principle of tailoring biologically active inputs to physiological demands.  

It is often discussed in the context of GLP-1 therapy from its role in preserving lean mass and physical performance during periods of reduced energy intake. As GLP-1 therapies can be associated with reductions in both fat mass and lean body mass during weight loss, researchers and HCPs have shown increasing interest in whether resistance exercise, adequate protein intake, and supplements such as creatine that is being discussed in relation to muscle health during weight loss, although evidence specific to people receiving GLP-1 therapy remains limited. However, evidence for creatine specifically in people receiving GLP-1 therapy remains limited, and further clinical research is ongoing. 

GLP-1 + Nutritional Compounds: Nutritional Considerations During Metabolic Care 

Alongside GLP-1 therapy, there is growing discussion around nutritional compounds used to support overall metabolic and functional health during treatment. These are not alternatives to GLP-1 medicines and do not alter their pharmacological mechanism but may be discussed as part of broader nutrition and lifestyle considerations under appropriate professional guidance. 

Common examples include creatine, protein supplementation, omega-3 fatty acids, dietary fiber, and electrolytes. Each has a distinct biological role, ranging from muscle protein synthesis and energy metabolism to areas such as dietary intake, hydration and general nutritional support. In particular, adequate dietary protein, whether through food or supplementation where appropriate, is commonly recommended as part of nutritional management during weight loss. 

Taken together, these adjunctive strategies sit alongside GLP-1 therapy rather than within its mechanism of action, reflecting a broader shift toward integrated, multi-component approaches to metabolic health 

GLP-1s vs. Compounded GLP-1s: Clarifying the Medicine, the Manufacturing, and the Adjunct Landscape 

GLP-1 therapy is increasingly embedded within a broader and more complex treatment landscape that includes both compounded formulations and nutritional compounds used alongside prescription medicines. While these categories are often discussed together, they represent distinct clinical, regulatory, and functional concepts. 

At its core, GLP-1 therapy remains a pharmacological intervention targeting appetite regulation and glycemic control. Compounded GLP-1 medicines exist within a separate framework of pharmacy preparation under specific clinical circumstances, while adjunct compounds such as creatine, protein, and other nutritional inputs operate outside the drug mechanism, supporting broader physiological needs such as muscle maintenance and metabolic resilience. 

Understanding these distinctions is becoming increasingly important as patient conversations evolve beyond single-treatment narratives toward more integrated discussions of metabolic health, treatment experience, and lifestyle adaptation. 

For those within the healthcare space, this shift highlights the value of analyzing real-life Patient conversations to better understand how these concepts are interpreted, combined, and discussed outside clinical settings. 

Disclaimer: This article is for informational purposes only and does not constitute medical advice, product promotion, or a recommendation to use any prescription medicine, compounded product, or supplement. GLP-1 medicines should only be used under the guidance of an appropriately qualified healthcare professional. Compounded products are not FDA-approved and are subject to specific legal and regulatory requirements. Nutritional supplements are not substitutes for prescription medicines. 

References 

• Balancing the benefits and risks of GLP-1 receptor agonists: a clinical guide for shared decision-making 
• Complementary And Alternative Medicine Market (2026-2033) 
• Creatine supplementation for preventing muscle atrophy in patients taking incretin-based pharmacotherapies: a perspective 
• Current Good Manufacturing Practice (CGMP) Regulations 
• Dietary supplement considerations during glucagon-like Peptide-1 receptor agonist treatment: A narrative review 
• FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss 
• GLP-1 medicines for weight loss and diabetes: what you need to know 
• Mayo Clinical: Preventing Muscle Loss with Creatine 
• Navigating Access: The Future of Compounded GLP-1 Receptor Agonists for Weight Loss 
• Shortage of GLP-1 receptor agonists (GLP-1RA) update 
• Step 3: Clinical Research 
• The expanding benefits of GLP-1 medicines